Patent details

92172 Product Name: "Solvat acétonique du cabazitaxel, ou désigné solvat acétonique du diméthoxy docetaxel ou solvat acétonique du (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phénylpropionate de 4-acetoxy-2a-benzoyloxy-5ß,20-époxy-1-hydroxy-7ß,10ß-diméthoxy-9-oxo-tax-11-ène-13a-yle (acétonate du cabazitaxel)"

Basic Information

Publication number:
92172
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP047873856
Legal Status:
Invalid
Application number:
92172
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/11/676/001 - JEVTANA-cabazitaxel
Marketing Authorization Type:
Marketing Authorization Date:
22/03/2011
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
20/03/2013
First Marketing Authorization date:
22/03/2011
Grant date:
21/05/2013
Activation date:
Publication date:
21/05/2013
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
22/03/2026
SPC Extension Expiration:
22/03/2026
Rejection date:
Withdrawal date:

Owner

From:
20/03/2013
 
 

Name:
Aventis Pharma S.A.
Address:
20, avenue Raymond Aron, 92160 Antony, France (FR)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
20/03/2013
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Inventor

1

Name:
PERRIN Marc-Antoine
Address:
France (FR)

2

Name:
DIDIER Eric
Address:
France (FR)

Publication

Bulletin

Bulletin Heading:
SPC4
Bulletin edition number:
2019/02
Publication date:
22/02/2019
Description:
Section F : Correction of granted supplementary protection certificates – I9 publication

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
03/01/2019 Publication 1
03/01/2019 Outgoing Correspondence 1
15/02/2016 Incoming Correspondence (Post) 4